COMMUNIQUÉS West-GlobeNewswire

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
11/02/2026
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically [...]
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
11/02/2026
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally supported [...]
Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board
11/02/2026
Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1, 2026 Industry expert [...]
SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments
11/02/2026
February 11, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the research consortium is coordinated by Philips, together with Erasmus MC as academic lead, and will combine advanced medical imaging and [...]
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
11/02/2026
Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy product Partnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 [...]
Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota
11/02/2026
The appointment of former General Manager of Novo Nordisk UK follows the recent appointment of Professor Sir Jonathan Van-Tam to Reset Health’s Advisory Board LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the [...]
InfiniHealth Medical Group Announces Integrated Multispecialty Care Model to Support Coordinated Specialty Services Across New Jersey
11/02/2026
WEST ORANGE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- InfiniHealth Medical Group today announced the continued advancement of its integrated multispecialty care model, a clinical framework that brings multiple board- [...]
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
11/02/2026
TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
Galecto Announces Pricing of $275 Million Underwritten Public Offering
11/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]
Berlin Protocol Performance Enhancer Product Information Updated — What Do Consumers Consider When Researching Male Enhancement Supplement Options in 2026?
11/02/2026
An informational overview examining what consumers research about Berlin Protocol Performance Enhancer, ingredient transparency in the male enhancement supplement category, and what publicly available product [...]
Picard Medical/ SynCardia to Present at European Mechanical Circulatory Support Summit and International Course on Mechanical Circulatory Support and New Technologies in Heart Failure
10/02/2026
TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved [...]
DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et discutera de l'avenir de l'EPIT lors du congrès annuel 2026 de l'AAAAI
10/02/2026
Châtillon, France, le 10 février (22 :30 CET) 2026 DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et [...]
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced [...]
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
10/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]
PetVivo Issues Correction and Replacement Press Release; Sets Fiscal Third Quarter 2026 Conference Call for Tuesday, February 17, 2026 at 5:00 p.m. ET
10/02/2026
MINNEAPOLIS, MN, US, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., in collaboration with its wholly-owned subsidiary PetVivo Animal Health (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering [...]
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
10/02/2026
Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment [...]
The Cooperative of American Physicians Announces Continued A+ (Superior) Rating for the Mutual Protection Trust
10/02/2026
Rating reaffirmed for the 19th consecutive year, reflecting long-term financial stability LOS ANGELES, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The Cooperative of American Physicians, Inc. (CAP) announced that AM Best has [...]
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
10/02/2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
11/02/2026
– Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET – WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory [...]

Pages